Prognostic factors for long-term infliximab treatment in Crohn's disease patients: a 20-year single centre experience

SummaryBackground The long-term efficacy of infliximab in patients with Crohn's disease is suboptimal. Aim To study prognostic factors for real-life long-term effcacy of infliximab in Crohn's disease. Methods All consecutive Crohn's disease patients treated with infliximab at a tertiary centre were retrospectively analysed. Only patients who received scheduled infliximab maintenance treatment were considered. Patient- and disease-related factors were used to identify independent predictors of infliximab failure-free survival using Cox proportional hazards regression. Results Of 1031 patients with Crohn's disease, 261 were eligible for inclusion. Median time on infliximab was 2.4 [IQR 1.4–4.7] years, and 65 (24.9%) patients experienced infliximab failure. Estimated 5-year infliximab failure-free survival was 65.9% (95% CI 58.3–73.5). Multivariate Cox regression identified disease duration ≥1 year (HR 2.5 (95% CI 1.2–5.2), P = 0.02), L1 disease location [HR 2.0 (1.1–3.5), P = 0.02], prior anti-TNF use [HR 2.3 (1.1–4.8), P = 0.03], haemoglobin